撤回:帝国的保护作用对乙氨基过量诱导的急性肝损伤
Oxidative medicine and cellular longevity
|November 24, 2025
概括
这篇文章已被撤回. 原来的研究研究.
科学领域:
- 科学出版业的科学出版.
- 撤回通知 撤回通知
背景情况:
- 文章 DOI: 10.1155/2020/8026838.8. 文章内容: 10.1155/2020/8026838. 文章内容: 10.1155/2020/8026838. 文章内容: 10.1155/2020/8026838. 文章内容: 10.1155/2020/8026838. 文章内容: 10.1155/2020/8026838. 文章内容: 10.1155/2020/8026838. 文章内容: 10.1155/2020/8026838. 文章内容: 文章内容: 文章内容: 文章内容: 文章内容: 文章内容: 文章内容: 文章内容: 文章内容: 文章内容:
研究的目的:
- 为了正式撤回识别的物品.
主要方法:
- 发出一个撤回通知.
主要成果:
- 这篇文章的DOI: 10.1155/2020/8026838.8. 这篇文章的DOI: 10.1155/2020/8026838. 不再被认为是科学记录的一部分.
结论:
- 撤回的文章不应该被引用或引用.
相关概念视频
Prevention of Further Absorption of Poison
1.2K
In cases of acute poisoning, the primary objective is to prevent further absorption of the toxic substance into the body. Immediate interventions using various decontamination techniques targeting the gastrointestinal (GI) tract can achieve this. Decontamination is crucial to prevent poison from entering the systemic circulation, which involves washing affected areas with water and mild soap and removing contaminated clothing. Once external decontamination is done, attention must be turned to...
1.2K
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
170
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
170
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
199
In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
199
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
204
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
204
Acute Kidney Injury IV: Diagnostic Studies and Prevention
249
Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
249
Anticholinesterase Agents: Poisoning and Treatment
1.5K
Anticholinesterases, also known as cholinesterase inhibitors, work by blocking the breakdown of acetylcholine, leading to its accumulation in the synaptic cleft. This accumulation indirectly enhances both muscarinic and nicotinic actions. These agents are classified as reversible or irreversible based on their mechanism of action.
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is...
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is...
1.5K


